MA45002B1 - Triple combinaison d'antagonistes purs du récepteurs 5-ht6, d'inhibiteurs de l'acétylcholinestérase et d'antagonistes du récepteur nmda - Google Patents
Triple combinaison d'antagonistes purs du récepteurs 5-ht6, d'inhibiteurs de l'acétylcholinestérase et d'antagonistes du récepteur nmdaInfo
- Publication number
- MA45002B1 MA45002B1 MA45002A MA45002A MA45002B1 MA 45002 B1 MA45002 B1 MA 45002B1 MA 45002 A MA45002 A MA 45002A MA 45002 A MA45002 A MA 45002A MA 45002 B1 MA45002 B1 MA 45002B1
- Authority
- MA
- Morocco
- Prior art keywords
- receptor antagonists
- pure
- nmda
- acetylcholinesterase inhibitors
- triple combination
- Prior art date
Links
- 239000000544 cholinesterase inhibitor Substances 0.000 title abstract 3
- 229940044551 receptor antagonist Drugs 0.000 title abstract 3
- 239000002464 receptor antagonist Substances 0.000 title abstract 3
- 108091005435 5-HT6 receptors Proteins 0.000 title abstract 2
- 229940127523 NMDA Receptor Antagonists Drugs 0.000 title 1
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 abstract 2
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 abstract 2
- 208000028698 Cognitive impairment Diseases 0.000 abstract 1
- 229940099433 NMDA receptor antagonist Drugs 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000003751 serotonin 6 antagonist Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Indole Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
La présente invention concerne une combinaison d'un antagoniste pur du récepteur 5-ht6, d'un inhibiteur de l'acétylcholinestérase et d'un antagoniste du récepteur nmda. La présente invention concerne également des antagonistes purs du récepteur 5-ht6 (5-ht6r), ou un ou plusieurs sels pharmaceutiquement acceptables de ceux-ci, en combinaison avec ou comme adjuvant à un inhibiteur de l'acétylcholinestérase et un antagoniste du récepteur de n-méthyl-d-aspartate (nmda), et leur utilisation dans le traitement de troubles cognitifs. La présente invention concerne en outre une composition pharmaceutique contenant ladite combinaison.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201641017204 | 2016-05-18 | ||
| PCT/IB2016/054672 WO2017199070A1 (fr) | 2016-05-18 | 2016-08-03 | Triple combinaison d'antagonistes purs du récepteurs 5-ht6, d'inhibiteurs de l'acétylcholinestérase et d'antagonistes du récepteur nmda |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA45002A MA45002A (fr) | 2019-03-27 |
| MA45002B1 true MA45002B1 (fr) | 2020-10-28 |
Family
ID=56896730
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA45002A MA45002B1 (fr) | 2016-05-18 | 2016-08-03 | Triple combinaison d'antagonistes purs du récepteurs 5-ht6, d'inhibiteurs de l'acétylcholinestérase et d'antagonistes du récepteur nmda |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US11253514B2 (fr) |
| EP (1) | EP3458039B1 (fr) |
| JP (1) | JP6629464B2 (fr) |
| KR (1) | KR102016120B1 (fr) |
| CN (1) | CN109152751A (fr) |
| AU (1) | AU2016407426B2 (fr) |
| BR (1) | BR112018073410A2 (fr) |
| CA (1) | CA3023836C (fr) |
| CY (1) | CY1123644T1 (fr) |
| DK (1) | DK3458039T3 (fr) |
| EA (1) | EA038087B1 (fr) |
| ES (1) | ES2815555T3 (fr) |
| HK (1) | HK1258022A1 (fr) |
| HR (1) | HRP20201412T1 (fr) |
| HU (1) | HUE052077T2 (fr) |
| IL (1) | IL262920B (fr) |
| LT (1) | LT3458039T (fr) |
| MA (1) | MA45002B1 (fr) |
| MD (1) | MD3458039T2 (fr) |
| MX (1) | MX384146B (fr) |
| NZ (1) | NZ747797A (fr) |
| PL (1) | PL3458039T3 (fr) |
| PT (1) | PT3458039T (fr) |
| RS (1) | RS60849B1 (fr) |
| SG (1) | SG11201809726UA (fr) |
| SI (1) | SI3458039T1 (fr) |
| SM (1) | SMT202000521T1 (fr) |
| WO (1) | WO2017199070A1 (fr) |
| ZA (1) | ZA201807310B (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019008484A1 (fr) * | 2017-07-03 | 2019-01-10 | Suven Life Sciences Limited | Nouvelles utilisations d'un antagoniste du récepteur 5-ht6 pur |
| JP7556031B2 (ja) * | 2019-12-02 | 2024-09-25 | スヴェン・ライフ・サイエンシーズ・リミテッド | 認知症患者の行動心理学的症状の治療 |
| ES3036880T3 (en) * | 2019-12-02 | 2025-09-25 | Suven Life Sciences Ltd | Combinations of masupirdine with donepezil or memantine for treating behavioral and psychological symptoms in patients with dementia |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL373903A1 (en) * | 2002-05-31 | 2005-09-19 | H.Lundbeck A/S | A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease |
| PT1581492E (pt) | 2002-11-28 | 2008-09-19 | Suven Life Sciences Ltd | Indoles n-arilsulfonil-3-substituídos possuindo afinidade de receptor de serotonina, processo para a sua preparação e composição farmacêutica contendo os mesmos |
| DK2521714T3 (en) * | 2010-01-05 | 2015-10-19 | Suven Life Sciences Ltd | Aromatic sulfone compositions useful in the treatment of central nervous disorders |
| CN105814020B (zh) * | 2013-12-02 | 2018-04-17 | 苏文生命科学有限公司 | 用于大规模生产1‑[(2‑溴苯基)磺酰基]‑5‑甲氧基‑3‑[(4‑甲基‑1‑哌嗪基)甲基]‑1h‑吲哚二甲磺酸盐一水合物的方法 |
| EP3134392B1 (fr) * | 2014-04-19 | 2019-01-02 | Sunshine Lake Pharma Co., Ltd. | Dérivés de sulfonamide et leurs applications pharmaceutiques |
-
2016
- 2016-08-03 SG SG11201809726UA patent/SG11201809726UA/en unknown
- 2016-08-03 HU HUE16763575A patent/HUE052077T2/hu unknown
- 2016-08-03 EP EP16763575.4A patent/EP3458039B1/fr active Active
- 2016-08-03 CN CN201680085589.7A patent/CN109152751A/zh active Pending
- 2016-08-03 RS RS20201045A patent/RS60849B1/sr unknown
- 2016-08-03 SM SM20200521T patent/SMT202000521T1/it unknown
- 2016-08-03 HK HK19100393.2A patent/HK1258022A1/zh unknown
- 2016-08-03 LT LTEP16763575.4T patent/LT3458039T/lt unknown
- 2016-08-03 PT PT167635754T patent/PT3458039T/pt unknown
- 2016-08-03 DK DK16763575.4T patent/DK3458039T3/da active
- 2016-08-03 MA MA45002A patent/MA45002B1/fr unknown
- 2016-08-03 KR KR1020187035888A patent/KR102016120B1/ko active Active
- 2016-08-03 HR HRP20201412TT patent/HRP20201412T1/hr unknown
- 2016-08-03 CA CA3023836A patent/CA3023836C/fr active Active
- 2016-08-03 JP JP2018559327A patent/JP6629464B2/ja active Active
- 2016-08-03 EA EA201892528A patent/EA038087B1/ru unknown
- 2016-08-03 BR BR112018073410-1A patent/BR112018073410A2/pt not_active Application Discontinuation
- 2016-08-03 US US16/097,752 patent/US11253514B2/en active Active
- 2016-08-03 ES ES16763575T patent/ES2815555T3/es active Active
- 2016-08-03 PL PL16763575T patent/PL3458039T3/pl unknown
- 2016-08-03 WO PCT/IB2016/054672 patent/WO2017199070A1/fr not_active Ceased
- 2016-08-03 AU AU2016407426A patent/AU2016407426B2/en active Active
- 2016-08-03 MX MX2018014184A patent/MX384146B/es unknown
- 2016-08-03 MD MDE20190349T patent/MD3458039T2/ro unknown
- 2016-08-03 SI SI201630909T patent/SI3458039T1/sl unknown
- 2016-08-03 NZ NZ747797A patent/NZ747797A/en unknown
-
2018
- 2018-10-31 ZA ZA2018/07310A patent/ZA201807310B/en unknown
- 2018-11-11 IL IL262920A patent/IL262920B/en active IP Right Grant
-
2020
- 2020-09-04 CY CY20201100834T patent/CY1123644T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA57972B1 (fr) | Inhibiteurs de parp1 | |
| MA48051B1 (fr) | Un sel de sodium du n-((1,2,3,5,6,7-hexahydro-s-indacen-4 -yl)carbamoyl)-1-isopropyl-1h-pyrazole-3-sulfonamide | |
| MA39094A1 (fr) | Polythérapie comprenant un inhibiteur de mdm2 et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers | |
| MA39211A1 (fr) | Composés tricycliques comme agents anti-cancers | |
| MA51204B1 (fr) | Formes pharmaceutiques comprenant un inhibiteur de la kallicréine plasmatique | |
| MA44674A (fr) | Inhibiteurs de bromodomaine | |
| MA39984B1 (fr) | Traitement d'affections malignes par lymphocytes b par un inhibiteur jak et pi3k combiné | |
| EA200971115A1 (ru) | Новые ингибиторы обратной транскриптазы вич | |
| MA45972B1 (fr) | Unité posologique orodispersible contenant un composant d'estétrol | |
| MA55821B1 (fr) | Antagonistes 5-ht2a destinés à être utilisés dans le traitement de la dépression | |
| RU2009120992A (ru) | Применение 3-андростандиола, необязательно в сочетании с агонистом 5-ht1а для лечения сексуальной дисфункции | |
| MA41634B1 (fr) | Formulation à base de combinaison de tésofensine et de métoprolol | |
| MA41633B1 (fr) | Composés amide en tant qu'agonistes du récepteur 5-ht4 | |
| MA45002B1 (fr) | Triple combinaison d'antagonistes purs du récepteurs 5-ht6, d'inhibiteurs de l'acétylcholinestérase et d'antagonistes du récepteur nmda | |
| MX2018003930A (es) | Inhibidores de calicreína plasmática humana. | |
| CL2007001826A1 (es) | Compuestos derivados de 2-(amino-sustituido)-benzotiazol-sulfonamida, inhibidores de proteasa, en particular, inhibidores de proteasa de vih; composicion farmaceutica; y uso para tratar o combatir una infeccion o enfermedad asociada con la infeccion de un retrovirus resistente a multiples farmacos. | |
| MA43876A (fr) | Compositions pharmaceutiques et leur utilisations contre les maladies de surcharge lysosomale | |
| MA45639B1 (fr) | Combinaison d'antagonistes purs du récepteur 5-ht6 avec des inhibiteurs d'acétylcholinestérase | |
| MA49839B1 (fr) | Inhibiteurs bicycliques de la histone déacétylase | |
| MA41985B1 (fr) | Composition pour le nettoyage du côlon et le traitement de troubles gastro-intestinaux | |
| MA45990A (fr) | Combinaison d'agonistes inverses du récepteur de l'histamine-3 avec des inhibiteurs de l'acétylcholinestérase | |
| FR3061021B1 (fr) | Antagoniste specifique de tlr4 dans le traitement du myelome multiple | |
| MA45988A (fr) | Triple combinaison d'agonistes inverses du récepteur d'histamine-3, d'inhibiteurs de l'acétylcholinestérase et d'antagonistes du récepteurs nmda | |
| MX378799B (es) | Combinación de antagonistas del receptor 5-ht6 puro con un antagonista del receptor nmda. | |
| MA41311B1 (fr) | Peptides antagonistes du cgrp |